APO Research
Talk to an analyst

APO RESEARCH · REPORT

Proto-Oncogene Drgu

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Proto-Oncogene Drgu Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

22 December 2025193 pages

Choose your research edition.

Industry ResearchProto-Oncogene Drgu Industry Research Report 2026126 pages · $2,950 USDIndustry Growth & TrendsGlobal Proto-Oncogene Drgu Industry Growth and Trends Forecast to 2032101 pages · $3,450 USDMarket StructureGlobal Proto-Oncogene Drgu Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032193 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Proto-Oncogene Drgu Market Outlook and Growth Opportunities 2026197 pages · $4,250 USDMarket Analysis & ForecastGlobal Proto-Oncogene Drgu Market Analysis and Forecast 2026-2032194 pages · $4,950 USD

Market perspective

The global Proto-Oncogene Drgu market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Proto-Oncogene Drgu is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Proto-Oncogene Drgu is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Proto-Oncogene Drgu is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Proto-Oncogene Drgu is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Proto-Oncogene Drgu include ARIAD Pharmaceuticals, Bayer Healthcare, Bristol-Myers Squibb, ChemGenex Pharmaceuticals, Dexa Medica, Exelixis, Onyx Pharmaceuticals, Plexxikon and AstraZeneca, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Proto-Oncogene Drgu market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Proto-Oncogene Drgu and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Proto-Oncogene Drgu sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Proto-Oncogene Drgu market size, projected growth trends, production technologies, key applications, and end-use industries.

Proto-Oncogene Drgu Segment by Company

ARIAD Pharmaceuticals

Bayer Healthcare

Bristol-Myers Squibb

ChemGenex Pharmaceuticals

Dexa Medica

Exelixis

Onyx Pharmaceuticals

Plexxikon

AstraZeneca

GlaxoSmithKline

Pfizer

Novartis

Eisai Pharmaceuticals

Proto-Oncogene Drgu Segment by Type

Imatinib (Gleevec)

Vemurafenib (Zelboraf)

Sorafenib (Nexavar)

Sunitinib (Sutent)

Pazopanib (Votrient)

Ponatinib (Iclusig)

Cabozantinib (Cabometyx and Cometriq)

Vandetanib (Caprelsa)

Dabrafenib (Tafinlar)

Axitinib (Inlyta)

Proto-Oncogene Drgu Segment by Application

Clinic

Hospital

Others

Proto-Oncogene Drgu Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Proto-Oncogene Drgu market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Proto-Oncogene Drgu and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Proto-Oncogene Drgu.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Proto-Oncogene Drgu market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Proto-Oncogene Drgu manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Proto-Oncogene Drgu in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Proto-Oncogene Drgu in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Proto-Oncogene Drgu Industry Trends Table 2. Proto-Oncogene Drgu Industry Drivers Table 3. Proto-Oncogene Drgu Industry Opportunities and Challenges Table 4. Proto-Oncogene Drgu Industry Restraints Table 5. Global Proto-Oncogene Drgu Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Proto-Oncogene Drgu Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Proto-Oncogene Drgu Sales by Manufacturers (k units) & (2021-2026) Table 8. Global Proto-Oncogene Drgu Sales Market Share by Manufacturers Table 9. Global Proto-Oncogene Drgu Average Sales Price (US$/unit) of Manufacturers (2021-2026) Table 10. Global Proto-Oncogene Drgu Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Proto-Oncogene Drgu Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Proto-Oncogene Drgu Manufacturers, Product Type & Application Table 13. Global Proto-Oncogene Drgu Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Proto-Oncogene Drgu by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Imatinib (Gleevec) Table 17. Major Manufacturers of Vemurafenib (Zelboraf) Table 18. Major Manufacturers of Sorafenib (Nexavar) Table 19. Major Manufacturers of Sunitinib (Sutent) Table 20. Major Manufacturers of Pazopanib (Votrient) Table 21. Major Manufacturers of Ponatinib (Iclusig) Table 22. Major Manufacturers of Cabozantinib (Cabometyx and Cometriq) Table 23. Major Manufacturers of Vandetanib (Caprelsa) Table 24. Major Manufacturers of Dabrafenib (Tafinlar) Table 25. Major Manufacturers of Axitinib (Inlyta) Table 26. Global Proto-Oncogene Drgu Sales by Type 2021 VS 2025 VS 2032 (k units) Table 27. Global Proto-Oncogene Drgu Sales by Type (2021-2026) & (k units) Table 28. Global Proto-Oncogene Drgu Sales by Type (2027-2032) & (k units) Table 29. Global Proto-Oncogene Drgu Sales Market Share by Type (2021-2026) Table 30. Global Proto-Oncogene Drgu Sales Market Share by Type (2027-2032) Table 31. Global Proto-Oncogene Drgu Revenue by Type 2021 VS 2025 VS 2032 (k units) Table 32. Global Proto-Oncogene Drgu Revenue by Type (2021-2026) & (k units) Table 33. Global Proto-Oncogene Drgu Revenue by Type (2027-2032) & (k units) Table 34. Global Proto-Oncogene Drgu Revenue Market Share by Type (2021-2026) Table 35. Global Proto-Oncogene Drgu Revenue Market Share by Type (2027-2032) Table 36. Major Manufacturers of Clinic Table 37. Major Manufacturers of Hospital Table 38. Major Manufacturers of Others Table 39. Global Proto-Oncogene Drgu Sales by Application 2021 VS 2025 VS 2032 (k units) Table 40. Global Proto-Oncogene Drgu Sales by Application (2021-2026) & (k units) Table 41. Global Proto-Oncogene Drgu Sales by Application (2027-2032) & (k units) Table 42. Global Proto-Oncogene Drgu Sales Market Share by Application (2021-2026) Table 43. Global Proto-Oncogene Drgu Sales Market Share by Application (2027-2032) Table 44. Global Proto-Oncogene Drgu Revenue by Application 2021 VS 2025 VS 2032 (k units) Table 45. Global Proto-Oncogene Drgu Revenue by Application (2021-2026) & (k units) Table 46. Global Proto-Oncogene Drgu Revenue by Application (2027-2032) & (k units) Table 47. Global Proto-Oncogene Drgu Revenue Market Share by Application (2021-2026) Table 48. Global Proto-Oncogene Drgu Revenue Market Share by Application (2027-2032) Table 49. Global Proto-Oncogene Drgu Sales by Region: 2021 VS 2025 VS 2032 (k units) Table 50. Global Proto-Oncogene Drgu Sales by Region (2021-2026) & (k units) Table 51. Global Proto-Oncogene Drgu Sales Market Share by Region (2021-2026) Table 52. Global Proto-Oncogene Drgu Sales Forecasted by Region (2027-2032) & (k units) Table 53. Global Proto-Oncogene Drgu Sales Forecasted Market Share by Region (2027-2032) Table 54. North America Proto-Oncogene Drgu Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 55. North America Proto-Oncogene Drgu Sales by Country (2021-2026) & (k units) Table 56. North America Proto-Oncogene Drgu Sales by Country (2027-2032) & (k units) Table 57. Europe Proto-Oncogene Drgu Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 58. Europe Proto-Oncogene Drgu Sales by Country (2021-2026) & (k units) Table 59. Europe Proto-Oncogene Drgu Sales by Country (2027-2032) & (k units) Table 60. Asia Pacific Proto-Oncogene Drgu Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 61. Asia Pacific Proto-Oncogene Drgu Sales by Country (2021-2026) & (k units) Table 62. Asia Pacific Proto-Oncogene Drgu Sales by Country (2027-2032) & (k units) Table 63. South America, Middle East and Africa Proto-Oncogene Drgu Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 64. South America, Middle East and Africa Proto-Oncogene Drgu Sales by Country (2021-2026) & (k units) Table 65. South America, Middle East and Africa Proto-Oncogene Drgu Sales by Country (2027-2032) & (k units) Table 66. Global Proto-Oncogene Drgu Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 67. Global Proto-Oncogene Drgu Revenue by Region (2021-2026) & (US$ Million) Table 68. Global Proto-Oncogene Drgu Revenue by Region (2027-2032) & (US$ Million) Table 69. Global Proto-Oncogene Drgu Revenue Market Share by Region (2021-2026) Table 70. Global Proto-Oncogene Drgu Revenue Market Share by Region (2027-2032) Table 71. ARIAD Pharmaceuticals Company Information Table 72. ARIAD Pharmaceuticals Business Overview Table 73. ARIAD Pharmaceuticals Proto-Oncogene Drgu Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 74. ARIAD Pharmaceuticals Proto-Oncogene Drgu Product Portfolio Table 75. ARIAD Pharmaceuticals Recent Development Table 76. Bayer Healthcare Company Information Table 77. Bayer Healthcare Business Overview Table 78. Bayer Healthcare Proto-Oncogene Drgu Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 79. Bayer Healthcare Proto-Oncogene Drgu Product Portfolio Table 80. Bayer Healthcare Recent Development Table 81. Bristol-Myers Squibb Company Information Table 82. Bristol-Myers Squibb Business Overview Table 83. Bristol-Myers Squibb Proto-Oncogene Drgu Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 84. Bristol-Myers Squibb Proto-Oncogene Drgu Product Portfolio Table 85. Bristol-Myers Squibb Recent Development Table 86. ChemGenex Pharmaceuticals Company Information Table 87. ChemGenex Pharmaceuticals Business Overview Table 88. ChemGenex Pharmaceuticals Proto-Oncogene Drgu Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 89. ChemGenex Pharmaceuticals Proto-Oncogene Drgu Product Portfolio Table 90. ChemGenex Pharmaceuticals Recent Development Table 91. Dexa Medica Company Information Table 92. Dexa Medica Business Overview Table 93. Dexa Medica Proto-Oncogene Drgu Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 94. Dexa Medica Proto-Oncogene Drgu Product Portfolio Table 95. Dexa Medica Recent Development Table 96. Exelixis Company Information Table 97. Exelixis Business Overview Table 98. Exelixis Proto-Oncogene Drgu Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 99. Exelixis Proto-Oncogene Drgu Product Portfolio Table 100. Exelixis Recent Development Table 101. Onyx Pharmaceuticals Company Information Table 102. Onyx Pharmaceuticals Business Overview Table 103. Onyx Pharmaceuticals Proto-Oncogene Drgu Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 104. Onyx Pharmaceuticals Proto-Oncogene Drgu Product Portfolio Table 105. Onyx Pharmaceuticals Recent Development Table 106. Plexxikon Company Information Table 107. Plexxikon Business Overview Table 108. Plexxikon Proto-Oncogene Drgu Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 109. Plexxikon Proto-Oncogene Drgu Product Portfolio Table 110. Plexxikon Recent Development Table 111. AstraZeneca Company Information Table 112. AstraZeneca Business Overview Table 113. AstraZeneca Proto-Oncogene Drgu Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 114. AstraZeneca Proto-Oncogene Drgu Product Portfolio Table 115. AstraZeneca Recent Development Table 116. GlaxoSmithKline Company Information Table 117. GlaxoSmithKline Business Overview Table 118. GlaxoSmithKline Proto-Oncogene Drgu Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 119. GlaxoSmithKline Proto-Oncogene Drgu Product Portfolio Table 120. GlaxoSmithKline Recent Development Table 121. Pfizer Company Information Table 122. Pfizer Business Overview Table 123. Pfizer Proto-Oncogene Drgu Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 124. Pfizer Proto-Oncogene Drgu Product Portfolio Table 125. Pfizer Recent Development Table 126. Novartis Company Information Table 127. Novartis Business Overview Table 128. Novartis Proto-Oncogene Drgu Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 129. Novartis Proto-Oncogene Drgu Product Portfolio Table 130. Novartis Recent Development Table 131. Eisai Pharmaceuticals Company Information Table 132. Eisai Pharmaceuticals Business Overview Table 133. Eisai Pharmaceuticals Proto-Oncogene Drgu Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 134. Eisai Pharmaceuticals Proto-Oncogene Drgu Product Portfolio Table 135. Eisai Pharmaceuticals Recent Development Table 136. Key Raw Materials Table 137. Raw Materials Key Suppliers Table 138. Proto-Oncogene Drgu Distributors List Table 139. Proto-Oncogene Drgu Customers List Table 140. Research Programs/Design for This Report Table 141. Authors List of This Report Table 142. Secondary Sources Table 143. Primary Sources List of Figures Figure 1. Proto-Oncogene Drgu Product Image Figure 2. Global Proto-Oncogene Drgu Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Proto-Oncogene Drgu Market Size (2021-2032) & (US$ Million) Figure 4. Global Proto-Oncogene Drgu Sales (2021-2032) & (k units) Figure 5. Global Proto-Oncogene Drgu Average Price (US$/unit) & (2021-2032) Figure 6. Global Top 5 and 10 Proto-Oncogene Drgu Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Imatinib (Gleevec) Image Figure 9. Vemurafenib (Zelboraf) Image Figure 10. Sorafenib (Nexavar) Image Figure 11. Sunitinib (Sutent) Image Figure 12. Pazopanib (Votrient) Image Figure 13. Ponatinib (Iclusig) Image Figure 14. Cabozantinib (Cabometyx and Cometriq) Image Figure 15. Vandetanib (Caprelsa) Image Figure 16. Dabrafenib (Tafinlar) Image Figure 17. Axitinib (Inlyta) Image Figure 18. Global Proto-Oncogene Drgu Sales by Type (2021 VS 2025 VS 2032) & (k units) Figure 19. Global Proto-Oncogene Drgu Sales Market Share 2021 VS 2025 VS 2032 Figure 20. Global Proto-Oncogene Drgu Sales Market Share by Type (2021-2032) Figure 21. Global Proto-Oncogene Drgu Revenue by Type (2021 VS 2025 VS 2032) & (k units) Figure 22. Global Proto-Oncogene Drgu Revenue Market Share 2021 VS 2025 VS 2032 Figure 23. Global Proto-Oncogene Drgu Revenue Market Share by Type (2021-2032) Figure 24. Clinic Image Figure 25. Hospital Image Figure 26. Others Image Figure 27. Global Proto-Oncogene Drgu Sales by Application (2021 VS 2025 VS 2032) & (k units) Figure 28. Global Proto-Oncogene Drgu Sales Market Share 2021 VS 2025 VS 2032 Figure 29. Global Proto-Oncogene Drgu Sales Market Share by Application (2021-2032) Figure 30. Global Proto-Oncogene Drgu Revenue by Application (2021 VS 2025 VS 2032) & (k units) Figure 31. Global Proto-Oncogene Drgu Revenue Market Share 2021 VS 2025 VS 2032 Figure 32. Global Proto-Oncogene Drgu Revenue Market Share by Application (2021-2032) Figure 33. North America Proto-Oncogene Drgu Sales and Growth Rate (2021-2032) & (k units) Figure 34. North America Proto-Oncogene Drgu Sales Market Share by Country (2021-2032) Figure 35. U.S. Proto-Oncogene Drgu Sales and Growth Rate (2021-2032) & (k units) Figure 36. Canada Proto-Oncogene Drgu Sales and Growth Rate (2021-2032) & (k units) Figure 37. Mexico Proto-Oncogene Drgu Sales and Growth Rate (2021-2032) & (k units) Figure 38. Europe Proto-Oncogene Drgu Sales and Growth Rate (2021-2032) & (k units) Figure 39. Europe Proto-Oncogene Drgu Sales Market Share by Country (2021-2032) Figure 40. Germany Proto-Oncogene Drgu Sales and Growth Rate (2021-2032) & (k units) Figure 41. France Proto-Oncogene Drgu Sales and Growth Rate (2021-2032) & (k units) Figure 42. U.K. Proto-Oncogene Drgu Sales and Growth Rate (2021-2032) & (k units) Figure 43. Italy Proto-Oncogene Drgu Sales and Growth Rate (2021-2032) & (k units) Figure 44. Netherlands Proto-Oncogene Drgu Sales and Growth Rate (2021-2032) & (k units) Figure 45. Asia Pacific Proto-Oncogene Drgu Sales and Growth Rate (2021-2032) & (k units) Figure 46. Asia Pacific Proto-Oncogene Drgu Sales Market Share by Country (2021-2032) Figure 47. China Proto-Oncogene Drgu Sales and Growth Rate (2021-2032) & (k units) Figure 48. Japan Proto-Oncogene Drgu Sales and Growth Rate (2021-2032) & (k units) Figure 49. South Korea Proto-Oncogene Drgu Sales and Growth Rate (2021-2032) & (k units) Figure 50. Southeast Asia Proto-Oncogene Drgu Sales and Growth Rate (2021-2032) & (k units) Figure 51. India Proto-Oncogene Drgu Sales and Growth Rate (2021-2032) & (k units) Figure 52. Australia Proto-Oncogene Drgu Sales and Growth Rate (2021-2032) & (k units) Figure 53. South America, Middle East and Africa Proto-Oncogene Drgu Sales and Growth Rate (2021-2032) & (k units) Figure 54. South America, Middle East and Africa Proto-Oncogene Drgu Sales Market Share by Country (2021-2032) Figure 55. Brazil Proto-Oncogene Drgu Sales and Growth Rate (2021-2032) & (k units) Figure 56. South Africa Proto-Oncogene Drgu Sales and Growth Rate (2021-2032) & (k units) Figure 57. Saudi Arabia Proto-Oncogene Drgu Sales and Growth Rate (2021-2032) & (k units) Figure 58. Turkey Proto-Oncogene Drgu Sales and Growth Rate (2021-2032) & (k units) Figure 59. Argentina Proto-Oncogene Drgu Sales and Growth Rate (2021-2032) & (k units) Figure 60. UAE Proto-Oncogene Drgu Sales and Growth Rate (2021-2032) & (k units) Figure 61. Egypt Proto-Oncogene Drgu Sales and Growth Rate (2021-2032) & (k units) Figure 62. Chile Proto-Oncogene Drgu Sales and Growth Rate (2021-2032) & (k units) Figure 63. Global Proto-Oncogene Drgu Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 64. Global Proto-Oncogene Drgu Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 65. North America Proto-Oncogene Drgu Revenue (2021-2032) & (US$ Million) Figure 66. North America Proto-Oncogene Drgu Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 67. Europe Proto-Oncogene Drgu Revenue (2021-2032) & (US$ Million) Figure 68. Europe Proto-Oncogene Drgu Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 69. Asia-Pacific Proto-Oncogene Drgu Revenue (2021-2032) & (US$ Million) Figure 70. Asia-Pacific Proto-Oncogene Drgu Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 71. South America, Middle East and Africa Proto-Oncogene Drgu Revenue (2021-2032) & (US$ Million) Figure 72. South America, Middle East and Africa Proto-Oncogene Drgu Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 73. Proto-Oncogene Drgu Value Chain Figure 74. Manufacturing Cost Structure Figure 75. Proto-Oncogene Drgu Production Mode & Process Figure 76. Direct Comparison with Distribution Share Figure 77. Distributors Profiles Figure 78. Years Considered Figure 79. Research Process Figure 80. Key Executives Interviewed

Scope & coverage.

Types
  • Imatinib (Gleevec)
  • Vemurafenib (Zelboraf)
  • Sorafenib (Nexavar)
  • Sunitinib (Sutent)
  • Pazopanib (Votrient)
  • Ponatinib (Iclusig)
  • Cabozantinib (Cabometyx and Cometriq)
  • Vandetanib (Caprelsa)
  • Dabrafenib (Tafinlar)
  • Axitinib (Inlyta)
Applications
  • Clinic
  • Hospital
  • Others
Companies covered
  • ARIAD Pharmaceuticals
  • Bayer Healthcare
  • Bristol-Myers Squibb
  • ChemGenex Pharmaceuticals
  • Dexa Medica
  • Exelixis
  • Onyx Pharmaceuticals
  • Plexxikon
  • AstraZeneca
  • GlaxoSmithKline
  • Pfizer
  • Novartis
  • Eisai Pharmaceuticals

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Proto-Oncogene Drgu Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Proto-Oncogene Drgu Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Proto-Oncogene Drgu Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Proto-Oncogene Drgu Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Proto-Oncogene Drgu Market Dynamics
  1. 2.1 Proto-Oncogene Drgu Industry Trends
  2. 2.2 Proto-Oncogene Drgu Industry Drivers
  3. 2.3 Proto-Oncogene Drgu Industry Opportunities and Challenges
  4. 2.4 Proto-Oncogene Drgu Industry Restraints
3 Proto-Oncogene Drgu Market by Manufacturers
  1. 3.1 Global Proto-Oncogene Drgu Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Proto-Oncogene Drgu Sales by Manufacturers (2021-2026)
  3. 3.3 Global Proto-Oncogene Drgu Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Proto-Oncogene Drgu Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Proto-Oncogene Drgu Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Proto-Oncogene Drgu Manufacturers, Product Type & Application
  7. 3.7 Global Proto-Oncogene Drgu Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Proto-Oncogene Drgu Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Proto-Oncogene Drgu Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Proto-Oncogene Drgu Tier 1, Tier 2, and Tier 3
4 Proto-Oncogene Drgu Market by Type
  1. 4.1 Proto-Oncogene Drgu Type Introduction
  2. 4.1.1 Imatinib (Gleevec)
  3. 4.1.2 Vemurafenib (Zelboraf)
  4. 4.1.3 Sorafenib (Nexavar)
  5. 4.1.4 Sunitinib (Sutent)
  6. 4.1.5 Pazopanib (Votrient)
  7. 4.1.6 Ponatinib (Iclusig)
  8. 4.1.7 Cabozantinib (Cabometyx and Cometriq)
  9. 4.1.8 Vandetanib (Caprelsa)
  10. 4.1.9 Dabrafenib (Tafinlar)
  11. 4.1.10 Axitinib (Inlyta)
  12. 4.2 Global Proto-Oncogene Drgu Sales by Type
  13. 4.2.1 Global Proto-Oncogene Drgu Sales by Type (2021 VS 2025 VS 2032)
  14. 4.2.2 Global Proto-Oncogene Drgu Sales by Type (2021-2032)
  15. 4.2.3 Global Proto-Oncogene Drgu Sales Market Share by Type (2021-2032)
  16. 4.3 Global Proto-Oncogene Drgu Revenue by Type
  17. 4.3.1 Global Proto-Oncogene Drgu Revenue by Type (2021 VS 2025 VS 2032)
  18. 4.3.2 Global Proto-Oncogene Drgu Revenue by Type (2021-2032)
  19. 4.3.3 Global Proto-Oncogene Drgu Revenue Market Share by Type (2021-2032)
5 Proto-Oncogene Drgu Market by Application
  1. 5.1 Proto-Oncogene Drgu Application Introduction
  2. 5.1.1 Clinic
  3. 5.1.2 Hospital
  4. 5.1.3 Others
  5. 5.2 Global Proto-Oncogene Drgu Sales by Application
  6. 5.2.1 Global Proto-Oncogene Drgu Sales by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Proto-Oncogene Drgu Sales by Application (2021-2032)
  8. 5.2.3 Global Proto-Oncogene Drgu Sales Market Share by Application (2021-2032)
  9. 5.3 Global Proto-Oncogene Drgu Revenue by Application
  10. 5.3.1 Global Proto-Oncogene Drgu Revenue by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Proto-Oncogene Drgu Revenue by Application (2021-2032)
  12. 5.3.3 Global Proto-Oncogene Drgu Revenue Market Share by Application (2021-2032)
6 Global Proto-Oncogene Drgu Sales by Region
  1. 6.1 Global Proto-Oncogene Drgu Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Proto-Oncogene Drgu Sales by Region (2021-2032)
  3. 6.2.1 Global Proto-Oncogene Drgu Sales by Region (2021-2026)
  4. 6.2.2 Global Proto-Oncogene Drgu Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Proto-Oncogene Drgu Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Proto-Oncogene Drgu Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Proto-Oncogene Drgu Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Proto-Oncogene Drgu Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Proto-Oncogene Drgu Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Proto-Oncogene Drgu Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Proto-Oncogene Drgu Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Proto-Oncogene Drgu Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Proto-Oncogene Drgu Revenue by Region
  1. 7.1 Global Proto-Oncogene Drgu Revenue by Region
  2. 7.1.1 Global Proto-Oncogene Drgu Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Proto-Oncogene Drgu Revenue by Region (2021-2026)
  4. 7.1.3 Global Proto-Oncogene Drgu Revenue by Region (2027-2032)
  5. 7.1.4 Global Proto-Oncogene Drgu Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Proto-Oncogene Drgu Revenue (2021-2032)
  8. 7.2.2 North America Proto-Oncogene Drgu Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Proto-Oncogene Drgu Revenue (2021-2032)
  11. 7.3.2 Europe Proto-Oncogene Drgu Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Proto-Oncogene Drgu Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Proto-Oncogene Drgu Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Proto-Oncogene Drgu Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Proto-Oncogene Drgu Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 ARIAD Pharmaceuticals
  2. 8.1.1 ARIAD Pharmaceuticals Company Information
  3. 8.1.2 ARIAD Pharmaceuticals Business Overview
  4. 8.1.3 ARIAD Pharmaceuticals Proto-Oncogene Drgu Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 ARIAD Pharmaceuticals Proto-Oncogene Drgu Product Portfolio
  6. 8.1.5 ARIAD Pharmaceuticals Recent Developments
  7. 8.2 Bayer Healthcare
  8. 8.2.1 Bayer Healthcare Company Information
  9. 8.2.2 Bayer Healthcare Business Overview
  10. 8.2.3 Bayer Healthcare Proto-Oncogene Drgu Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Bayer Healthcare Proto-Oncogene Drgu Product Portfolio
  12. 8.2.5 Bayer Healthcare Recent Developments
  13. 8.3 Bristol-Myers Squibb
  14. 8.3.1 Bristol-Myers Squibb Company Information
  15. 8.3.2 Bristol-Myers Squibb Business Overview
  16. 8.3.3 Bristol-Myers Squibb Proto-Oncogene Drgu Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Bristol-Myers Squibb Proto-Oncogene Drgu Product Portfolio
  18. 8.3.5 Bristol-Myers Squibb Recent Developments
  19. 8.4 ChemGenex Pharmaceuticals
  20. 8.4.1 ChemGenex Pharmaceuticals Company Information
  21. 8.4.2 ChemGenex Pharmaceuticals Business Overview
  22. 8.4.3 ChemGenex Pharmaceuticals Proto-Oncogene Drgu Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 ChemGenex Pharmaceuticals Proto-Oncogene Drgu Product Portfolio
  24. 8.4.5 ChemGenex Pharmaceuticals Recent Developments
  25. 8.5 Dexa Medica
  26. 8.5.1 Dexa Medica Company Information
  27. 8.5.2 Dexa Medica Business Overview
  28. 8.5.3 Dexa Medica Proto-Oncogene Drgu Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Dexa Medica Proto-Oncogene Drgu Product Portfolio
  30. 8.5.5 Dexa Medica Recent Developments
  31. 8.6 Exelixis
  32. 8.6.1 Exelixis Company Information
  33. 8.6.2 Exelixis Business Overview
  34. 8.6.3 Exelixis Proto-Oncogene Drgu Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Exelixis Proto-Oncogene Drgu Product Portfolio
  36. 8.6.5 Exelixis Recent Developments
  37. 8.7 Onyx Pharmaceuticals
  38. 8.7.1 Onyx Pharmaceuticals Company Information
  39. 8.7.2 Onyx Pharmaceuticals Business Overview
  40. 8.7.3 Onyx Pharmaceuticals Proto-Oncogene Drgu Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Onyx Pharmaceuticals Proto-Oncogene Drgu Product Portfolio
  42. 8.7.5 Onyx Pharmaceuticals Recent Developments
  43. 8.8 Plexxikon
  44. 8.8.1 Plexxikon Company Information
  45. 8.8.2 Plexxikon Business Overview
  46. 8.8.3 Plexxikon Proto-Oncogene Drgu Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Plexxikon Proto-Oncogene Drgu Product Portfolio
  48. 8.8.5 Plexxikon Recent Developments
  49. 8.9 AstraZeneca
  50. 8.9.1 AstraZeneca Company Information
  51. 8.9.2 AstraZeneca Business Overview
  52. 8.9.3 AstraZeneca Proto-Oncogene Drgu Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 AstraZeneca Proto-Oncogene Drgu Product Portfolio
  54. 8.9.5 AstraZeneca Recent Developments
  55. 8.10 GlaxoSmithKline
  56. 8.10.1 GlaxoSmithKline Company Information
  57. 8.10.2 GlaxoSmithKline Business Overview
  58. 8.10.3 GlaxoSmithKline Proto-Oncogene Drgu Sales, Price, Revenue and Gross Margin (2021-2026)
  59. 8.10.4 GlaxoSmithKline Proto-Oncogene Drgu Product Portfolio
  60. 8.10.5 GlaxoSmithKline Recent Developments
  61. 8.11 Pfizer
  62. 8.11.1 Pfizer Company Information
  63. 8.11.2 Pfizer Business Overview
  64. 8.11.3 Pfizer Proto-Oncogene Drgu Sales, Price, Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Pfizer Proto-Oncogene Drgu Product Portfolio
  66. 8.11.5 Pfizer Recent Developments
  67. 8.12 Novartis
  68. 8.12.1 Novartis Company Information
  69. 8.12.2 Novartis Business Overview
  70. 8.12.3 Novartis Proto-Oncogene Drgu Sales, Price, Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Novartis Proto-Oncogene Drgu Product Portfolio
  72. 8.12.5 Novartis Recent Developments
  73. 8.13 Eisai Pharmaceuticals
  74. 8.13.1 Eisai Pharmaceuticals Company Information
  75. 8.13.2 Eisai Pharmaceuticals Business Overview
  76. 8.13.3 Eisai Pharmaceuticals Proto-Oncogene Drgu Sales, Price, Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Eisai Pharmaceuticals Proto-Oncogene Drgu Product Portfolio
  78. 8.13.5 Eisai Pharmaceuticals Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Proto-Oncogene Drgu Value Chain Analysis
  2. 9.1.1 Proto-Oncogene Drgu Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Proto-Oncogene Drgu Production Mode & Process
  6. 9.2 Proto-Oncogene Drgu Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Proto-Oncogene Drgu Distributors
  9. 9.2.3 Proto-Oncogene Drgu Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst